Press Room

2017 CPhI Worldwide

Start
Tuesday, October 24, 2017 - 08:00
End
Thursday, October 26, 2017 - 18:00
Location: Frankfurt, Germany
Booth Number: 111F21

Hovione will be attending CPhI Worldwide 2017 in Frankfurt, Germany. An event that is considered the world's leading European pharmaceutical exhibition, which brings together more than 42,000 pharma industry professionals from 150+ countries.

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

 

the leader in spray drying | Hovione

Hovione, the Leader in Spray Drying



Combining the largest capacity, the best scale-up science and the most experienced team, you can trust Hovione to take your project from development to market.

  • Hovione offers a number of innovative Particle Engineering technologies, at all scales, to address challenges in drug delivery.
  • More than 13 years of expertise in commercial Spray Drying.
API Plus products | Hovione

API+

Enabling Novel Formulations Through Engineered Drug Product Intermediate

  • Targeted lung delivery
  • Taste masking
  • Controlled release
  • Modified solubility
  • Improved stability
  • Nanoparticles

The Experts in Customized API for Inhalation

Hovione is using its advanced technologies to enhance API's performance and offer a range of customized Drug Product Intermediates.

Hovione inhalation grade APIs are designed at the particle level to bring unique performance to your formulation.



hovione-customized-apis-for-inhalation



Hovione provides the peace of mind of a high quality manufacturer who is a founding member of Rx-360 and has an unblemished regulatory track record.

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

We look forward to meeting you at our booth # 111F21 at the Messe Frankfurt in Germany.

 

 

 

You might be also interested in:

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026